Oramed Pharmaceuticals Inc. (ORMP) shareholders
Close on Nov 13, 2026Market cap $154.33MP/E 1.1Yield 6.74%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Nadav Kidron | 3,116,729 | 7.60% | 13D (active) amendment | Feb 11, 2025 |
| BML Investment Partners, L.P. | 2,643,907 | 6.55% | 13G (passive) amendment | Dec 31, 2024 |
| Aquamarine Financial (Cayman) Ltd | 2,512,175 | 6.04% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ORMP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Mercer Global Advisors Inc /Adv | 3,810,540 | 9.16% | $18.33M | +1,900,000 | 0.02% |
| Aquamarine Financial (Cayman) Ltd | 2,512,175 | 6.04% | $12.08M | +399,863 | 0.67% |
| Gem Investment Advisors, LLC | 1,998,802 | 4.81% | $9.61M | +358,733 | 5.89% |
| BlackRock, Inc. | 1,608,111 | 3.87% | $7.74M | +1,515,919 | 0.00% |
| Murchinson Ltd. | 1,290,294 | 3.10% | $6.21M | −25,000 | 0.86% |
| BML Capital Management, LLC | 866,269 | 2.08% | $4.17M | −2,300,962 | 2.37% |
| Boothbay Fund Management, LLC | 578,638 | 1.39% | $2.78M | −22,078 | 0.04% |
| Geode Capital Management, LLC | 500,690 | 1.20% | $2.41M | +476,408 | 0.00% |
| Goldman Sachs Group Inc | 253,293 | 0.61% | $1.22M | New | 0.00% |
| State Street Corp | 242,100 | 0.58% | $1.16M | New | 0.00% |
| Rathbones Group PLC | 233,018 | 0.56% | $1.12M | −233,018 | 0.00% |
| Vanguard Portfolio Management LLC | 229,882 | 0.55% | $1.11M | New | 0.00% |
| Dimensional Fund Advisors LP | 202,609 | 0.49% | $973.78K | +44,400 | 0.00% |
| Northern Trust Corp | 184,920 | 0.44% | $889.47K | New | 0.00% |
| Renaissance Technologies LLC | 183,800 | 0.44% | $884.08K | +36,100 | 0.00% |
| Wells Fargo & Company/Mn | 166,000 | 0.40% | $798.46K | +8,414 | 0.00% |
| Bank Of America Corp /De/ | 150,694 | 0.36% | $724.84K | +4,542 | 0.00% |
| Strs Ohio | 133,800 | 0.32% | $643.58K | New | 0.00% |
| Jane Street Group, LLC | 113,349 | 0.27% | $545.21K | +60,809 | 0.00% |
| O'Shaughnessy Asset Management, LLC | 102,962 | 0.25% | $495.25K | −13,401 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 84 | 17M | 40.3% | 29 / 21 | 20 / 8 | 7M | 3M |
| Q1 2026 | 64 | 13M | 32.4% | 16 / 19 | 16 / 8 | 3M | 1M |
| Q4 2025 | 57 | 13M | 32.1% | 15 / 14 | 10 / 5 | 5M | 1M |
| Q3 2025 | 47 | 9M | 22.1% | 5 / 9 | 10 / 5 | 2M | 0M |
| Q2 2025 | 47 | 7M | 17.5% | 4 / 8 | 15 / 9 | 0M | 1M |
| Q1 2025 | 52 | 8M | 18.7% | 4 / 15 | 18 / 8 | 1M | 0M |
| Q4 2024 | 56 | 8M | 18.4% | 9 / 14 | 17 / 8 | 1M | 0M |
| Q3 2024 | 55 | 7M | 16.7% | 8 / 14 | 14 / 11 | 1M | 0M |
| Q2 2024 | 59 | 6M | 14.3% | 10 / 12 | 15 / 2 | 1M | 1M |
| Q1 2024 | 51 | 5M | 12.9% | 8 / 14 | 12 / 13 | 1M | 1M |
| Q4 2023 | 56 | 5M | 12.6% | 9 / 18 | 10 / 9 | 3M | 0M |
| Q3 2023 | 56 | 2M | 5.5% | 14 / 12 | 14 / 6 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
48 funds held ORMP in Q2 2026, 73% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ORMP | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Russell 2000 ETF | 634,585 | 1.53% | $3.05M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 378,478 | 0.91% | $1.54M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 318,598 | 0.77% | $1.53M | 0.01% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 114,970 | 0.28% | $553.01K | 0.04% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 83,634 | 0.20% | $340.39K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 63,616 | 0.15% | $305.99K | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Value Index Fund | 48,747 | 0.12% | $234.47K | 0.01% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 46,404 | 0.11% | $188.86K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 40,483 | 0.10% | $164.77K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 36,536 | 0.09% | $148.70K | 0.00% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 33,545 | 0.08% | $161.35K | 0.00% | Jun 30, 2026 |
| Nationwide Bailard Small Cap Value Fund | 32,478 | 0.08% | $132.19K | 0.10% | Jul 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 28,155 | 0.07% | $111.78K | 0.00% | May 31, 2026 |
| LVIP State Street Small-Cap Index Fund | 25,700 | 0.06% | $123.62K | 0.01% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 24,282 | 0.06% | $96.40K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Miriam Kidron | Chief Scientific Officer, Director | 2,149,554 | 5.17% | Nov 13, 2026 |
| Nadav Kidron | President and CEO, Director | 5,583,505 | 13.42% | Nov 13, 2026 |
| Joshua Hexter | COO & CBO | 1,927,130 | 4.63% | Nov 13, 2026 |
| Avraham Gabay | Chief Financial Officer | 1,460,076 | 3.51% | Nov 13, 2026 |
| Yehuda Reznick | Director | 180,850 | 0.43% | Nov 13, 2026 |
| Arie Mayer | Director | 242,259 | 0.58% | Nov 13, 2026 |
| Benjamin Shapiro | Director | 2,097,050 | 5.04% | Nov 13, 2026 |
| Daniel Aghion | Director | 189,111 | 0.45% | Nov 13, 2026 |
| Leonard Sank | Director | 273,420 | 0.66% | Jun 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yehuda Reznick Director | Nov 12, 2026 | Award | +2,890 | – | – | 180,850 |
| Yehuda Reznick Director | Nov 12, 2026 | Award | +72,780 | – | – | 177,960 |
| Daniel Aghion Director | Nov 12, 2026 | Award | +2,890 | – | – | 189,111 |
| Daniel Aghion Director | Nov 12, 2026 | Award | +72,780 | – | – | 186,221 |
| Arie Mayer Director | Nov 12, 2026 | Award | +1,470 | – | – | 242,259 |
| Arie Mayer Director | Nov 12, 2026 | Award | +72,780 | – | – | 240,789 |
| Benjamin Shapiro Director | Nov 12, 2026 | Award | +1,050 | – | – | 197,050 |
| Benjamin Shapiro Director | Nov 12, 2026 | Award | +72,780 | – | – | 196,000 |
| Nadav Kidron President and CEO, Director | Nov 12, 2026 | Award | +688,000 | – | – | 5,457,505 |
| Nadav Kidron President and CEO, Director | Nov 12, 2026 | Award | +629,000 | – | – | 4,769,505 |
| Miriam Kidron Chief Scientific Officer, Director | Nov 12, 2026 | Award | +242,000 | – | – | 2,149,554 |
| Miriam Kidron Chief Scientific Officer, Director | Nov 12, 2026 | Award | +357,000 | – | – | 1,907,554 |
| Joshua Hexter COO & CBO | Nov 12, 2026 | Award | +242,000 | – | – | 1,927,130 |
| Joshua Hexter COO & CBO | Nov 12, 2026 | Award | +357,000 | – | – | 1,685,130 |
| Avraham Gabay Chief Financial Officer | Nov 12, 2026 | Award | +242,000 | – | – | 1,460,076 |
| Avraham Gabay Chief Financial Officer | Nov 12, 2026 | Award | +357,000 | – | – | 1,218,076 |
| Avraham Gabay Chief Financial Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −20,000 | $4.51 | $90.20K | 861,076 |
| Joshua Hexter COO & CBO | Oct 1, 2026 | Sale(10b5-1 plan) | −30,000 | $4.51 | $135.33K | 1,328,130 |
| Nadav Kidron President and CEO, Director | Sep 24, 2026 | Award | +349,497 | – | – | 3,771,740 |
| Nadav Kidron President and CEO, Director | Sep 24, 2026 | Award | +368,765 | – | – | 4,140,505 |
| Avraham Gabay Chief Financial Officer | Sep 24, 2026 | Award | +209,291 | – | – | 881,076 |
| Miriam Kidron Chief Scientific Officer, Director | Sep 24, 2026 | Award | +208,125 | – | – | 1,341,263 |
| Miriam Kidron Chief Scientific Officer, Director | Sep 24, 2026 | Award | +209,291 | – | – | 1,550,554 |
| Joshua Hexter COO & CBO | Sep 24, 2026 | Award | +209,291 | – | – | 1,358,130 |
| Joshua Hexter COO & CBO | Sep 24, 2026 | Award | +75,455 | – | – | 1,148,839 |
| Joshua Hexter COO & CBO | Jul 2, 2026 | Option exercise | +50,000 | $3.69 | $184.50K | 1,073,384 |
| Avraham Gabay Chief Financial Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −73,360 | $4.51 | $330.85K | 671,785 |
| Joshua Hexter COO & CBO | Jul 1, 2026 | Sale(10b5-1 plan) | −137,000 | $4.46 | $611.02K | 1,023,384 |
| Miriam Kidron Chief Scientific Officer, Director | Mar 30, 2026 | Tax withholding | −435,084 | $3.31 | $1.44M | 1,133,138 |
| Nadav Kidron President and CEO, Director | Mar 30, 2026 | Tax withholding | −44,818 | $3.31 | $148.35K | 3,422,243 |
| Joshua Hexter COO & CBO | Mar 17, 2026 | Award | +95,889 | – | – | 1,160,384 |
| Nadav Kidron President and CEO, Director | Mar 17, 2026 | Award | +167,005 | – | – | 3,422,243 |
| Miriam Kidron Chief Scientific Officer, Director | Mar 17, 2026 | Award | +119,558 | – | – | 1,568,222 |
| Avraham Gabay Chief Financial Officer | Mar 17, 2026 | Award | +95,889 | – | – | 745,145 |
| Nadav Kidron President and CEO, Director | Mar 12, 2026 | Gift | −100,000 | – | – | 3,255,238 |
| Nadav Kidron President and CEO, Director | Jan 22, 2026 | Option exercise | +109,000 | – | – | 3,355,238 |
| Avraham Gabay Chief Financial Officer | Jan 22, 2026 | Option exercise | +19,000 | – | – | 649,256 |
| Miriam Kidron Chief Scientific Officer, Director | Jan 22, 2026 | Option exercise | +19,000 | – | – | 1,448,664 |
| Joshua Hexter COO & CBO | Jan 22, 2026 | Option exercise | +19,000 | – | – | 1,064,495 |
| Miriam Kidron Chief Scientific Officer, Director | Jan 14, 2026 | Gift | −86,166 | – | – | 1,343,498 |
| Benjamin Shapiro Director | Dec 31, 2025 | Award | +3,500 | – | – | 123,220 |
| Benjamin Shapiro Director | Dec 31, 2025 | Award | +30,000 | – | – | 119,720 |
| Nadav Kidron President and CEO, Director | Dec 31, 2025 | Award | +232,640 | – | – | 2,919,238 |
| Nadav Kidron President and CEO, Director | Dec 31, 2025 | Award | +327,000 | – | – | 3,246,238 |
| Yehuda Reznick Director | Dec 31, 2025 | Award | +30,000 | – | – | 98,930 |
| Yehuda Reznick Director | Dec 31, 2025 | Award | +6,250 | – | – | 105,180 |
| Joshua Hexter COO & CBO | Dec 31, 2025 | Award | +115,000 | – | – | 1,045,495 |
| Joshua Hexter COO & CBO | Dec 31, 2025 | Award | +97,328 | – | – | 930,495 |
| Arie Mayer Director | Dec 31, 2025 | Award | +4,900 | – | – | 168,009 |
| Arie Mayer Director | Dec 31, 2025 | Award | +30,000 | – | – | 163,109 |
| Miriam Kidron Chief Scientific Officer, Director | Dec 31, 2025 | Award | +115,000 | – | – | 1,429,664 |
| Miriam Kidron Chief Scientific Officer, Director | Dec 31, 2025 | Award | +121,331 | – | – | 1,314,664 |
| Avraham Gabay Chief Financial Officer | Dec 31, 2025 | Award | +81,216 | – | – | 515,256 |
| Avraham Gabay Chief Financial Officer | Dec 31, 2025 | Award | +115,000 | – | – | 630,256 |
| Daniel Aghion Director | Dec 31, 2025 | Award | +30,000 | – | – | 107,191 |
| Daniel Aghion Director | Dec 31, 2025 | Award | +6,250 | – | – | 113,441 |
| Daniel Aghion Director | Jun 5, 2025 | Award | +30,000 | – | – | 68,820 |
| Daniel Aghion Director | Jun 5, 2025 | Award | +8,371 | – | – | 77,191 |
| Benjamin Shapiro Director | Jun 5, 2025 | Award | +30,000 | – | – | 85,070 |
| Benjamin Shapiro Director | Jun 5, 2025 | Award | +4,650 | – | – | 89,720 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Oramed Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 15,643 shares on Aug 26, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Joshua Hexter Officer | Oct 1, 2026 | 30,000 | $140.10K | Oct 1, 2026 | Shares issued upon vesting of RSUs |
| Avi Gabay Officer | Oct 1, 2026 | 20,000 | $93.40K | Oct 1, 2026 | Shares issued upon vesting of RSUs |
| Joshua Hexter Officer | Jul 1, 2026 | 137,000 | $658.97K | Jul 1, 2026 | Shares issued upon vesting of RSUs |
| Avraham Gabay Officer | Jul 1, 2026 | 93,360 | $449.06K | Jul 1, 2026 | Shares issued upon vesting of RSUs |
See a number that looks wrong?